Milnubes / Curiosity, with sourcesBotany · Culture · Science
Cannabinoid atlas / Reference entry
HHCP
Semisynthetic & derivatives

Hexahydrocannabiphorol

HHCP is a chemical identity distinct from HHC, not an alternative name for the same substance. Research combines sample analysis, receptor activity and clinical cases; it does not yet establish a therapeutic profile or a reliable comparison of human effects.

Microscope objectives above the sample platform.
Stock photograph providing context for this entry. It does not document a trial, participant, identified product or HHCP result.
Evidence map

Mixed evidence by question. This label summarises the type of data; it is neither a recommendation to use nor a safety rating.

How we read studies and personal accounts ↗

Identity

HHCP has a seven-carbon side chain, compared with five in HHC. The 9R and 9S forms have been identified. Its commercial classification as semisynthetic does not demonstrate the specific origin of each sample.

Terms associated with this entry: HHC-P, HHCp, hexahydrocannabiphorol, HHC-C7.

More letters do not provide a potency scale

A cellular study found that HHCP activates CB1 as a partial agonist and that its epimers differ. Translating that signal into ‘so many times stronger’ in people would require a different kind of study. The experimental system, measured endpoint and composition matter; comparing isolated numbers is insufficient.

The sample may tell another story

Researchers studying one commercial HHCP sample identified several accompanying compounds, including isomers. Their findings supported a synthetic origin for that sample. The result does not describe every product, but shows why ‘hemp-derived’ is not a complete analytical description.

What a clinical case contributes

A case published in 2024 described difficulty articulating words and vomiting after exposure to an HHCP-containing product. A case alerts us to a possible problem; it cannot estimate its frequency or attribute every effect of a commercial product to a pure molecule.

What has been studied

Laboratory or animals

CB1 activity does not demonstrate efficacy against pain, anxiety or insomnia.

Risks and gaps

Clinical literature contains poisonings associated with HHCP products; data are insufficient to establish a safety profile.

Documented forms

Cartridges and concentrated samplesThese are matrices described in analytical studies, not recommended product forms.

A molecule and a product are different things. Read about flowers, resins, oils, creams, capsules and vaping.

Experiences

We have not included a verifiable individual account in this review. We do not fill that gap with commercial stories or invented experiences.

Conclusion

HHCP requires sample identification and a distinction between receptor data and clinical consequences. The length of a chemical chain does not sum up that complexity.

Legal context

Read the Spain note and official sources. Absence from a cited list does not establish that a product is lawful.

Sources

  1. Identification of HHC, dihydro-iso-THC and HHCP in electronic cigarette cartridge products · Laboratory study
  2. Isolation and characterization of synthesis intermediates and side products in hexahydrocannabiphorol · Laboratory study
  3. In vitro activation of the CB1 receptor by HHC, HHC-O and HHC-P · Laboratory study
  4. A Case of Acute Intoxication from Sublingually Administering a Liquid Inhalation Product Containing a Marijuana Analogue · Original research

Source review: 2026-11-02. No external clinical review. Corrections: info@milnubes.com.